In addition, Devos et al. assessed the levels of IL-6 in the plasma of 109 ALS patients at the beginning of a clinical trial (NCT00868166) with ALSFRS-R measurements up to 18 months. This evidence concerns the gene IL6 and amyotrophic lateral sclerosis.